Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 3/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | ESRRG | P62508 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28771713 | 0.85 | CES2 (0.57) | RAB9ANPC1ALDH1A1MAPTHPGD | |
| SCHEMBL9734572 | 0.84 | LMNA (0.50) | SNCAKDM4ELMNAHSD17B10ESR1 | |
| SCHEMBL28440957 | 0.81 | SNCA (0.50) | SNCAKDM4ELMNAHSD17B10ESR1 | |
| SCHEMBL9735515 | 0.81 | HDAC3 (0.51) | SNCAKDM4ELMNAHSD17B10ESR1 | |
| SCHEMBL29471126 | 0.79 | PTPN1 (0.57) | SNCAKDM4ELMNAHSD17B10ESR1 | |
| SCHEMBL1701124 | 0.79 | PTPN1 (0.57) | SNCAKDM4ELMNAHSD17B10ESR1 | |
| SCHEMBL4597302 | 0.79 | MAPT (0.55) | SNCAKDM4ELMNAHSD17B10ESR1 | |
| SCHEMBL5455143 | 0.79 | KDM4E (0.49) | SNCAKDM4ELMNAHSD17B10ESR1 | |
| SCHEMBL10695452 | 0.78 | TDP1 (0.45) | SNCAKDM4ELMNAHSD17B10ESR1 | |
| SCHEMBL8053366 | 0.77 | GRIN2B (0.44) | SNCAKDM4ELMNAHSD17B10ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790763-B2 | Substituted phenyl methanone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-09-07 | — | — | US | disclosed |
| EP-1843767-B1 | 2,5-DISUBSTITUTED PHENYL METHANONE DERIVATIVES AS GLYCINE TRANSPORTER 1 (GLYT-1) INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS. | HOFFMANN LA ROCHE (CH) | 2009-07-08 | — | — | EP | disclosed |
| EP-1843767-A1 | 2,5-DISUBSTITUTED PHENYL METHANONE DERIVATIVES AS GLYCINE TRANSPORTER 1 (GLYT-1) INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS. | F. Hoffmann-Roche AG (CH) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006077026-A1 | 2, 5-DISUBSTITUTED PHENYL METHANONE DERIVATIVES AS GLYCINE TRANSPORTER 1 (GLYT-I) INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRY DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-07-27 | — | — | WO | disclosed |
| US-20060160788-A1 | Substituted phenyl methanone derivatives | HOFFMANN-LA ROCHE INC. | 2006-07-20 | — | — | US | disclosed |
| EP-1070708-B1 | Triazole derivatives | HOFFMANN LA ROCHE (CH) | 2004-01-14 | — | — | EP | disclosed |
| US-6265426-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | HOFFMANN-LA ROCHE INC. | 2001-07-24 | — | — | US | disclosed |
| EP-1070708-A1 | Triazole and imidazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2001-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160788-A1 | Substituted phenyl methanone derivatives | SLC6A5, SLC6A1, SLC1A1 | SNCA 517/4885KDM4E 3640/4885LMNA 3619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.